MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-06-2026
Smith & Nephew plc General and Administrative Expenses 2011-2026 | SNN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Smith & Nephew plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.1 B | 3.1 B | 3.06 B | 2.88 B | 2.72 B | 387 M | 403 M | 367 M | 351 M | 314 M | 369 M | 464 M | 451 M | 443 M | 2.1 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.1 B | 314 M | 1.37 B |
Quarterly General and Administrative Expenses Smith & Nephew plc
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.1 B | 3.1 B | 3.06 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.1 B | 3.06 B | 3.09 B |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B |  USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
45.8 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.62 | 1.53 % | $ 329 M | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
499 M | $ 8.07 | -2.36 % | $ 1.21 B | USA |
 |
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
14.1 M | $ 4.4 | 2.33 % | $ 165 M |  France |
 |
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.29 | - | $ 50.5 M | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.03 | 1.62 % | $ 17.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.47 | 2.17 % | $ 29.2 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
120 M | $ 17.95 | -2.29 % | $ 421 M | USA |
 |
Delcath Systems
DCTH
|
43.5 M | $ 10.82 | -1.81 % | $ 388 M | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
LENSAR
LNSR
|
45.2 M | $ 5.93 | -2.63 % | $ 70.9 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
LivaNova PLC
LIVN
|
549 M | $ 75.4 | 2.13 % | $ 4.11 B |  Britain |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Pulmonx Corporation
LUNG
|
101 M | $ 1.53 | -1.61 % | $ 62.2 M | USA |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | USA |
 |
MiMedx Group
MDXG
|
56.5 M | $ 3.68 | 1.52 % | $ 544 M | USA |
 |
Electromed
ELMD
|
39.3 M | $ 37.92 | -0.78 % | $ 321 M | USA |
 |
Myomo
MYO
|
14 M | $ 1.01 | -2.4 % | $ 42.3 M | USA |
 |
Butterfly Network
BFLY
|
39.2 M | $ 4.53 | 1.23 % | $ 1.12 B | USA |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | USA |
 |
Orthofix Medical
OFIX
|
554 M | $ 9.68 | -9.95 % | $ 383 M |  Curacao |
 |
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
1.18 B | $ 85.56 | 0.88 % | $ 11.6 B | USA |
 |
Profound Medical Corp.
PROF
|
32.1 M | $ 6.9 | 1.02 % | $ 209 M | Canada |
 |
Insulet Corporation
PODD
|
1.16 B | $ 153.94 | -0.6 % | $ 10.8 B | USA |
 |
CONMED Corporation
CNMD
|
132 M | $ 36.21 | -2.74 % | $ 1.12 B | USA |
 |
Sintx Technologies
SINT
|
6.2 M | $ 2.38 | -0.5 % | $ 6.6 M | USA |
 |
Inspire Medical Systems
INSP
|
625 M | $ 42.53 | -2.99 % | $ 1.25 B | USA |
 |
Integer Holdings Corporation
ITGR
|
212 M | $ 90.59 | 1.47 % | $ 3.15 B | USA |
 |
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 87.76 | 2.31 % | $ 51.3 B | USA |
 |
TransMedics Group
TMDX
|
185 M | $ 69.89 | 1.39 % | $ 2.38 B | USA |